GCP
ANVS icon

GSA Capital Partners’s Annovis Bio ANVS Stock Holding History

GSA Capital Partners’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93K Buy
49,904
+4,481
+10% +$8.71K 0.01% 1629
2026
Q1 		$101K Buy
+45,423
New +$125K 0.01% 1562

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's ANVS Position: Q2 2026 in Review

GSA Capital Partners increased its Annovis Bio (ANVS) stake by 9.9% in Q2 2026, buying an estimated $8.71K and bringing the position to 49,904 shares worth $93K. The position accounts for 0.01% of the portfolio, ranked #1629.

GSA Capital Partners first reported a position in ANVS in Q1 2026 and has held it in 2 quarters since. The position peaked at $101K in Q1 2026. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • GSA Capital Partners held 49,904 shares of Annovis Bio worth $93K as of Q2 2026.
  • GSA Capital Partners bought 4,481 Annovis Bio shares in Q2 2026, an estimated $8.71K.
  • Annovis Bio made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1629 holding.
  • GSA Capital Partners first reported a position in Annovis Bio in Q1 2026 and has held it in 2 quarters since.
  • GSA Capital Partners's Annovis Bio position peaked at $101K in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.